2. Academic Validation
  3. Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy

Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy

  • Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3047-3057. doi: 10.1007/s00259-020-04832-9.
Simone Krebs 1,  Joseph A O'Donoghue 2,  Evan Biegel 2,  Bradley J Beattie 2,  Diane Reidy 3,  Serge K Lyashchenko 4 5 6,  Jason S Lewis 4 5 6,  Lisa Bodei 4 6,  Wolfgang A Weber 4 6 7,  Neeta Pandit-Taskar 4 6
Affiliations

Affiliations

  • 1 Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. krebss@mskcc.org.
  • 2 Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • 3 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • 4 Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
  • 5 Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • 6 Department of Radiology, Weill Cornell Medical College, New York, NY, USA.
  • 7 Department of Nuclear Medicine, Technical University of Munich, Munich, Germany.
PMID: 32378020 DOI: 10.1007/s00259-020-04832-9
Abstract

Purpose: Paired imaging/therapy with radiolabeled Somatostatin Receptor (SSTR) antagonists is a novel approach in neuroendocrine tumors (NETs). The aim of this study was to compare tumor uptake of 68Ga-DOTA-JR11 and 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) in patients with NETs.

Methods: As part of a prospective clinical trial, 20 patients with metastatic NETs underwent 68Ga-DOTA-JR11 PET/CT and serial imaging with 177Lu-satoreotide tetraxetan. PET/CT and SPECT/CT parameters for lesion uptake and absorbed dose of 177Lu-satoreotide tetraxetan in lesions were compared using linear regression analysis and Pearson correlation.

Results: A total of 95 lesions were analyzed on 68Ga-DOTA-JR11 PET/CT and 177Lu-satoreotide tetraxetan SPECT/CT. SUVs and tumor-to-normal-tissue ratios on PET/CT and SPECT/CT were significantly correlated (p < 0.01), but the degree of correlation was modest with Pearson correlation coefficients ranging from 0.3 to 0.7. Variation in intrapatient lesional correlation was observed. Nevertheless, in all patients, the lesion SUVpeak uptake ratio for 177Lu-satoreotide tetraxetan vs. 68Ga-DOTA-JR11 was high; even in those with low uptake on 68Ga-DOTA-JR11 PET/CT (SUVpeak ≤ 10), a ratio of 8.0 ± 5.2 was noted. Correlation of SUVpeak of 68Ga-DOTA-JR11 with projected 177Lu-satoreotide tetratexan-absorbed dose (n = 42) was modest (r = 0.5, p < 0.01), while excellent correlation of SUVpeak of 177Lu-satoreotide tetraxetan with projected 177Lu-satoreotide tetraxetan-absorbed dose was noted (r = 0.9, p < 0.0001).

Conclusion: Our study shows that 68Ga-DOTA-JR11 PET can be used for patient selection and PRRT and that low tumor uptake on PET should not preclude patients from treatment with 177Lu-satoreotide tetraxetan. The ability to use single time-point SPECT/CT for absorbed dose calculations could facilitate dosimetry regimens, save costs, and improve patient convenience.

Keywords

177Lu-satoreotide tetraxetan; 68Ga-DOTA-JR11; Dosimetry; Neuroendocrine tumors; Somatostatin receptor antagonists.

Figures
Products